CORESTEMCHEMON Past Earnings Performance
Past criteria checks 0/6
CORESTEMCHEMON's earnings have been declining at an average annual rate of -9.1%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 15.3% per year.
Key information
-9.1%
Earnings growth rate
-4.8%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 15.3% |
Return on equity | -90.2% |
Net Margin | -52.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry
Mar 05Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?
Apr 12If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns
Feb 16Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?
Dec 25Revenue & Expenses BreakdownBeta
How CORESTEMCHEMON makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 33,657 | -17,672 | 9,551 | 12,763 |
30 Sep 23 | 41,377 | -11,391 | 9,505 | 12,823 |
30 Jun 23 | 44,821 | -12,465 | 8,803 | 11,984 |
31 Mar 23 | 48,101 | -6,240 | 10,429 | 11,297 |
31 Dec 22 | 45,878 | -2,257 | 9,321 | 11,385 |
30 Sep 22 | 41,633 | 4,485 | -2,116 | 20,674 |
30 Jun 22 | 39,492 | 7,476 | 300 | 17,527 |
31 Mar 22 | 34,068 | -14,523 | 5,543 | 13,397 |
31 Dec 21 | 30,240 | -6,999 | 5,667 | 12,131 |
30 Sep 21 | 30,054 | -30,830 | 10,874 | 5,883 |
30 Jun 21 | 28,593 | -30,936 | 8,709 | 5,883 |
31 Mar 21 | 26,694 | -13,782 | 5,572 | 6,514 |
31 Dec 20 | 26,358 | -23,187 | 5,362 | 5,883 |
30 Sep 20 | 25,381 | -8,244 | 9,828 | 1,594 |
30 Jun 20 | 24,552 | -6,399 | 8,446 | 2,286 |
31 Mar 20 | 24,783 | -5,637 | 5,563 | 4,376 |
31 Dec 19 | 24,284 | -5,168 | 5,458 | 3,850 |
30 Sep 19 | 23,741 | -3,623 | 4,684 | 3,392 |
30 Jun 19 | 24,598 | -2,892 | 4,753 | 3,328 |
31 Mar 19 | 21,926 | -3,857 | 4,837 | 3,106 |
31 Dec 18 | 22,317 | -3,397 | 4,865 | 2,933 |
30 Sep 18 | 18,889 | -3,578 | 5,411 | 3,654 |
30 Jun 18 | 17,553 | -3,891 | 5,088 | 3,565 |
31 Mar 18 | 19,178 | -3,220 | 5,028 | 3,448 |
31 Dec 17 | 18,094 | -4,007 | 4,930 | 3,160 |
30 Sep 17 | 19,883 | -3,253 | 4,016 | 2,791 |
30 Jun 17 | 20,077 | -2,022 | 4,298 | 2,253 |
31 Mar 17 | 19,541 | -1,795 | 4,608 | 1,864 |
31 Dec 16 | 17,953 | -1,664 | 4,966 | 1,489 |
30 Sep 16 | 18,510 | -801 | 4,627 | 668 |
30 Jun 16 | 18,661 | -1,332 | 4,790 | 668 |
31 Mar 16 | 18,733 | -725 | 4,303 | 668 |
31 Dec 15 | 18,571 | -512 | 3,609 | 668 |
30 Sep 15 | 16,785 | -2,990 | 3,754 | 978 |
30 Jun 15 | 14,636 | -5,562 | 3,545 | 978 |
31 Mar 15 | 13,986 | -6,133 | 3,642 | 978 |
31 Dec 14 | 12,988 | -6,802 | 3,997 | 978 |
31 Dec 13 | 3,655 | -3,575 | 2,634 | 547 |
Quality Earnings: A166480 is currently unprofitable.
Growing Profit Margin: A166480 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A166480 is unprofitable, and losses have increased over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare A166480's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A166480 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A166480 has a negative Return on Equity (-90.16%), as it is currently unprofitable.